Fulgent Genetics (FLGT) Competitors

Addus HomeCare (NASDAQ:ADUS) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk, valuation, dividends and media sentiment.

Does the MarketBeat Community prefer ADUS or FLGT?

Addus HomeCare received 82 more outperform votes than Fulgent Genetics when rated by MarketBeat users. Likewise, 68.78% of users gave Addus HomeCare an outperform vote while only 60.10% of users gave Fulgent Genetics an outperform vote.

Company	Underperform	Outperform
Addus HomeCare	Outperform Votes 326 68.78%	Underperform Votes 148 31.22%
Fulgent Genetics	Outperform Votes 244 60.10%	Underperform Votes 162 39.90%

Do insiders and institutionals hold more shares of ADUS or FLGT?

95.4% of Addus HomeCare shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 4.6% of Addus HomeCare shares are held by insiders. Comparatively, 31.8% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is ADUS or FLGT more profitable?

Addus HomeCare has a net margin of 6.50% compared to Fulgent Genetics' net margin of -59.39%. Addus HomeCare's return on equity of 9.62% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addus HomeCare	6.50%	9.62%	7.37%
Fulgent Genetics	-59.39%	-1.81%	-1.66%

Which has more risk and volatility, ADUS or FLGT?

Addus HomeCare has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Fulgent Genetics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.

Do analysts rate ADUS or FLGT?

Addus HomeCare presently has a consensus target price of $134.22, suggesting a potential upside of 22.88%. Fulgent Genetics has a consensus target price of $22.00, suggesting a potential upside of 33.66%. Given Fulgent Genetics' higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than Addus HomeCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addus HomeCare	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Fulgent Genetics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the media prefer ADUS or FLGT?

In the previous week, Addus HomeCare had 7 more articles in the media than Fulgent Genetics. MarketBeat recorded 8 mentions for Addus HomeCare and 1 mentions for Fulgent Genetics. Addus HomeCare's average media sentiment score of 1.27 beat Fulgent Genetics' score of 0.00 indicating that Addus HomeCare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addus HomeCare	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has stronger earnings and valuation, ADUS or FLGT?

Addus HomeCare has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addus HomeCare	$1.06B	1.87	$62.52M	$4.37	25.00
Fulgent Genetics	$289.21M	1.74	-$167.82M	-$5.52	-2.98

Summary

Addus HomeCare beats Fulgent Genetics on 16 of the 19 factors compared between the two stocks.